From: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
a) Patients, treatment and variables | ||||
---|---|---|---|---|
Study and marker | Remarks | |||
Marker (If non-binary: how was marker analyzed? continuous or categorical. If categorical, how were cutpoints determined?) | M = ploidy (diploid, aneuploid) | |||
Further variables (variables collected, variables available for analysis, baseline variables, patient and tumor variables) | v1 = age, v2 = histologic type, v3 = grade, v4 = residual tumor, v5 = stage, v6 = ascitesa, v7 = estrogena, v8 = progesteronea, v9 = CA-125a | |||
Patients | n | Remarks | ||
Assessed for eligibility | 257 | Disease: Advanced ovarian cancer, stage III and IV Patient source: Surgery 1982 to 1990, University Hospital Freiburg Sample source: Archived specimens available | ||
Excluded | 73 | General exclusion criteriab, non-standard therapyb, coefficient of variation > 7%b | ||
Included | 184 | Previously untreated. Treatment: all had platinum based chemotherapy after surgery | ||
With outcome events | 139 | Overall survival: death from any cause | ||
b) Statistical analyses of survival outcomes | ||||
Analysis | Patients | Events | Variables considered | Results/remarks |
A1: Univariable | 184 | 139 | M, v1 to v5 | Table 2, Figure 1 |
A2: Multivariable | 174 | 133 | M, v1, v3 to v5 | Table 3 [v2 omitted because many missing data; Backward selection, see text] |
A3: Effect for ploidy adjusted for v4 | 184 | 139 | M, v4 | Figure 2 [Based on result of A2] |
A4: Interaction: ploidy and stage | 175 | 133 | M, v1, v2, v4, v5 | See text |
A5: Ploidy in stage subgroups | Â | Â | Â | Â |
v5 = III | 128 | 88 | M | Figure 3 |
v5 = IV | 56 | 51 | M | Figure 4 |